Volume | 376,099 |
|
|||||
News | - | ||||||
Day High | 0.74 | Low High |
|||||
Day Low | 0.71 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
HOOKIPA Pharma Inc | HOOK | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.7255 | 0.71 | 0.74 | 0.712 | 0.7204 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
629 | 376,099 | $ 0.7273521 | $ 273,556 | - | 0.41 - 2.05 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:29 | 2 | $ 0.73 | USD |
HOOKIPA Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
59.6M | 83.95M | - | 14.25M | -64.92M | -0.77 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
HOOKIPA Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HOOK Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.7095 | 0.75 | 0.6996 | 0.713848 | 360,678 | 0.0127 | 1.79% |
1 Month | 0.805 | 0.85 | 0.6631 | 0.7456367 | 428,836 | -0.0828 | -10.29% |
3 Months | 0.8024 | 0.85 | 0.5789 | 0.7080413 | 550,479 | -0.0802 | -10.00% |
6 Months | 0.63 | 1.13 | 0.41 | 0.7748026 | 1,466,753 | 0.0922 | 14.63% |
1 Year | 0.76 | 2.05 | 0.41 | 0.917791 | 1,185,618 | -0.0378 | -4.97% |
3 Years | 13.68 | 20.00 | 0.41 | 2.04 | 1,193,207 | -12.96 | -94.72% |
5 Years | 14.00 | 20.00 | 0.41 | 2.45 | 757,536 | -13.28 | -94.84% |
HOOKIPA Pharma Description
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies. |